egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
– Study Led by Philippe Généreux, MD, and Colleagues was Presented Today at the 2024 ACC Annual Meeting – – Key Findings Demonstrate Untreated... Read more.
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks More than 75% of... Read more.
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment... Read more.
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone... Read more.
Wipro Appoints Srini Pallia as CEO & Managing Director
EAST BRUNSWICK, N.J. & BENGALURU, India–(BUSINESS WIRE)–$WIPRO #CEO–Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology... Read more.
The United States Army and United Football League Announce Exclusive Partnership; U.S. Army Becomes the Presenting Partner of the UFL
WASHINGTON & ARLINGTON, Texas–(BUSINESS WIRE)–The United Football League (“UFL”) today announced an exclusive partnership with The United States... Read more.
Tempus Introduces Workspaces into its Lens Data Analytics Platform
Lens is trusted by nearly 100 institutions to uncover novel insights CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision... Read more.
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse SOMERSET, N.J.–(BUSINESS WIRE)–Legend... Read more.
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now... Read more.
Avangrid Statement on Gas Subsidiaries’ Response to 4.8 Magnitude Earthquake
New York State Electric & Gas (NYSEG), Southern Connecticut Gas (SCG), Connecticut Natural Gas (CNG), and Berkshire Gas Company (BGC) assessing for damage to... Read more.